Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 17103
Country/Region: Tanzania
Year: 2017
Main Partner: Baylor College of Medicine
Main Partner Program: International Pediatric AIDS Initiative-Tanzania
Organizational Type: University
Funding Agency: USAID
Total Funding: $1,750,370 Additional Pipeline Funding: $196,874

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: TB/HIV (HVTB) $6,030
Care: Pediatric Care and Support (PDCS) $0
Testing: HIV Testing and Counseling (HVCT) $4,718
Treatment: Adult Treatment (HTXS) $35,764
Treatment: Pediatric Treatment (PDTX) $1,703,858
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 4,307
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2018 1,030
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2018 142
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2018 150
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2018 130
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2018 28
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2018 130
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2018 123
HTS_TST Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative 2018 180
HTS_TST Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative 2018 180
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2018 43
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2018 40
HTS_TST Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative 2018 3
HTS_TST Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative 2018 1
HTS_TST Service Delivery Point (Facility)Other PITC: <1, Negative 2018 383
HTS_TST Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative 2018 561
HTS_TST Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative 2018 507
HTS_TST Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative 2018 193
HTS_TST Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative 2018 63
HTS_TST Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Negative 2018 1
HTS_TST Sum of Test Result disaggregates 2018 359
HTS_TST_POS By Test Result: Positive 2018 359
HTS_TST_POS Service Delivery Point (Facility) Other PITC: <1, Positive 2018 3
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 1-9, Positive 2018 70
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive 2018 7
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive 2018 10
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2018 20
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2018 3
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2018 23
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2018 13
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive 2018 43
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive 2018 23
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2018 17
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive 2018 69
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive 2018 37
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive 2018 47
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive 2018 34
TB_PREV By Age/Sex (Numerator): <15, Female 2018 6
TB_PREV By Age/Sex (Numerator): <15, Male 2018 10
TB_PREV By Age/Sex (Numerator): 15+, Female 2018 57
TB_PREV By Age/Sex (Numerator): 15+, Male 2018 86
TB_PREV By Therapy type (Numerator): 6-12 Month IPT 2018 159
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2018 159
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2018 317
TB_PREV_den By Age/Sex (Denominator): <15, Female 2018 13
TB_PREV_den By Age/Sex (Denominator): <15, Male 2018 19
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2018 114
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2018 171
TB_PREV_den By Therapy type (Denominator): 6-12 Month IPT 2018 317
TX_CURR Age/Sex: <1 2018 23
TX_CURR Age/Sex: <1-9 2018 651
TX_CURR Age/Sex: 10-14 Female 2018 302
TX_CURR Age/Sex: 10-14 Male 2018 289
TX_CURR Age/Sex: 15-19 Female 2018 53
TX_CURR Age/Sex: 15-19 Male 2018 47
TX_CURR Age/Sex: 20-24 Female 2018 17
TX_CURR Age/Sex: 20-24 Male 2018 2
TX_CURR Age/Sex: 25-49 Female 2018 11
TX_CURR Age/Sex: 25-49 Male 2018 1
TX_CURR Aggregated Age/Sex: <15 Female 2018 449
TX_CURR Aggregated Age/Sex: <15 Male 2018 421
TX_CURR Aggregated Age/Sex: 15+ Female 2018 95
TX_CURR Aggregated Age/Sex: 15+ Male 2018 124
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 2,486
TX_CURR Sum of age/sex disaggregates 2018 100
TX_CURR Sum of Aggregated Age/Sex <15 2018 870
TX_CURR Sum of Aggregated Age/Sex 15+ 2018 219
TX_CURR Sum of Aggregated Age/Sex disaggregates 2018 1,089
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2018 72
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2018 43
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2018 26
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2018 12
TX_NEW By Age/Sex: <1 2018 78
TX_NEW By Age/Sex: 1-9 2018 101
TX_NEW By Age/Sex: 10-14 Female 2018 27
TX_NEW By Age/Sex: 10-14 Male 2018 16
TX_NEW By Age/Sex: 15-19 Female 2018 19
TX_NEW By Age/Sex: 15-19 Male 2018 23
TX_NEW By Age/Sex: 20-24 Female 2018 8
TX_NEW By Age/Sex: 25-49 Female 2018 23
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 448
TX_NEW Sum of Age/Sex disaggregates 2018 116
TX_NEW Sum of Aggregated Age/Sex disaggregates 2018 153
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 1,865
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 1,678
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 563
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 62
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 523
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 58
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 238
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 27
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 185
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 21
TX_PVLS Numerator: Indication: Routine 2018 1,510
TX_PVLS Numerator: Indication: Targeted 2018 168
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 625
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 70
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 581
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 64
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 264
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 29
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 207
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 23
TX_PVLS_den Denominator: Indication: Routine 2018 1,678
TX_PVLS_den Denominator: Indication: Targeted 2018 187
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 155
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 138
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 53
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 35
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 381
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 448
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 182
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 162
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 63
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 41
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 2,361
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 59
TX_TB Numerator: By Aggregated Age/Sex: <15, Female 2018 2
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2018 4
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2018 21
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2018 32
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2018 94
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2018 142
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2018 849
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2018 1,275
TX_TB_den Denominator: By Screen Result: Negative 2018 2,302
TX_TB_den Denominator: By Screen Result: Positive 2018 59
Cross Cutting Budget Categories and Known Amounts Total: $569,852
Gender: Gender Based Violence (GBV) $12,267
GBV Prevention
Food and Nutrition: Commodities $29,837
Human Resources for Health $250,000
Economic Strengthening $29,494
Education $99,676
Food and Nutrition: Policy, Tools, and Service Delivery $148,578